Baricitinib Noninferior to Etanercept for Reducing Ultrasound-Assessed Synovitis

A phase IV trial shows baricitinib, with or without methotrexate, matches etanercept in objective measures of joint inflammation.

For Doctors in a Hurry

Clinicians require data comparing baricitinib to established biologic therapies for managing active rheumatoid arthritis in patients failing methotrexate.
This phase IV trial randomized 150 adults with active rheumatoid arthritis into three parallel treatment groups over 24 weeks.
At week 12, baricitinib monotherapy and combination therapy demonstrated noninferiority to etanercept plus methotrexate regarding ultrasound-assessed synovitis scores (P < .050).
The researchers concluded that baricitinib effectively reduces joint inflammation, as measured by ultrasound, compared to standard etanercept treatment regimens.
These findings support baricitinib as a clinically equivalent option for reducing synovitis in patients who have an inadequate methotrexate response.

Objective Assessment of Synovial Inflammation in Targeted RA Therapy

Managing active rheumatoid arthritis often necessitates a transition to targeted therapies for patients who do not achieve adequate control with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) [1, 2]. While clinical response is frequently assessed using composite indices like the American College of Rheumatology (ACR) criteria, these measures can be confounded by subjective patient-reported outcomes, including individual perceptions of pain and fatigue [3, 4]. Although oral Janus kinase (JAK) inhibitors such as baricitinib have shown efficacy in achieving clinical remission and slowing radiographic progression, with ACR20 response rates of 70% at 12 weeks in methotrexate-inadequate responders, clinicians require objective confirmation that these agents suppress active joint inflammation as effectively as established injectable biologics [5, 6, 7, 8, 9]. A recent international multicenter trial of 150 patients provides this evidence, demonstrating that baricitinib is noninferior to etanercept in reducing the Global European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology Synovitis Score (GLOESS), a standardized ultrasound measure of synovial tissue inflammation (p < 0.050) [10].

Trial Design and Standardized Ultrasound Scoring

This randomized, active-controlled, international, multicenter, phase IV clinical trial enrolled 150 adult patients (109 women and 41 men) with active rheumatoid arthritis and a history of inadequate response to methotrexate. The study compared three parallel treatment arms: baricitinib monotherapy, baricitinib plus methotrexate, and etanercept plus methotrexate. To track disease activity, researchers conducted clinical, ultrasound, and laboratory assessments at baseline and at 4, 12, and 24 weeks. The primary endpoint focused on the Global European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology Synovitis Score (GLOESS), a composite metric that quantifies joint inflammation across the bilateral wrist and metacarpophalangeal joints. Synovitis was graded on a scale of 0 to 3 using B-mode (gray-scale imaging that visualizes structural changes like synovial thickening), Doppler mode (which detects increased blood flow associated with active inflammation), and a combination of both. To establish noninferiority, the researchers required that the reduction in GLOESS for the baricitinib groups remain above a lower limit of 80% of the changes observed in the etanercept plus methotrexate group, a statistical threshold used to ensure the new treatment is not unacceptably less effective than the standard of care.

Rapid Inflammatory Suppression and Noninferiority Results

The primary analysis confirmed that baricitinib provides an objective reduction in joint inflammation comparable to a standard tumor necrosis factor inhibitor. Specifically, noninferiority of baricitinib monotherapy against etanercept with methotrexate was confirmed for GLOESS at week 12 (P < .050), and noninferiority of baricitinib plus methotrexate against etanercept with methotrexate was also confirmed (P < .050). These results suggest that Janus kinase inhibition can match the efficacy of biological disease-modifying antirheumatic drugs in suppressing synovial thickening and hypervascularity, offering a potent oral alternative for patients who prefer to avoid injections. The therapeutic effect was rapid, with all clinical and ultrasound variables showing significant improvement starting from week 4 across all three treatment arms (P < .050). This early response was sustained through the 24-week study period. Furthermore, the researchers found that changes in metalloprotease-3 (an enzyme that serves as a biomarker for cartilage and bone degradation) concentration significantly correlated with changes in all ultrasound scores. This correlation is clinically significant because it suggests that the reduction in ultrasound-detected synovitis is a reliable proxy for the suppression of the underlying biological processes that lead to permanent joint damage.

Study Info

Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial

Esperanza Naredo, Otto Olivas-Vergara, Pablo E. Borges, Sheila Recuero-Díaz, et al.

Journal Annals of the Rheumatic Diseases

Published April 01, 2026